Key result
CPVT1-iPS cell-derived cardiomyocytes exhibited arrhythmias, delayed afterdepolarizations after catecholaminergic stimulation, and higher amplitudes and longer durations of spontaneous Ca2+ release.
Population
Human induced pluripotent stem cells derived from dermal fibroblasts of healthy donors and a patient with…
Comparison
In vitro modeling using iPS cell-derived… vs iPS cell-derived cardiomyocytes from healthy…
Design
Preclinical
Authors
Loading...
iPS models for CPVT1 warrant cautious interpretation; leaves open clinical translation pending validation.
Patient-specific iPSC-derived cardiomyocytes carrying a novel RYR2 mutation successfully recapitulate the CPVT1 arrhythmic phenotype in vitro, offering a platform for disease modeling and drug testing.
Fatima et al. (2011) studied Catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1). CPVT1-iPS cell-derived cardiomyocytes (RYR2 p.F2483I mutation) vs. Healthy donor iPS cell-derived cardiomyocytes was evaluated on Arrhythmias, delayed afterdepolarizations (DADs), and calcium release events. CPVT1-iPS cell-derived cardiomyocytes exhibited arrhythmias, delayed afterdepolarizations after catecholaminergic stimulation, and higher amplitudes and longer durations of spontaneous Ca2+ release.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: